These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 15472106)

  • 21. [Immune factors in atherosclerosis].
    Pasqui AL; Bova G; Maffei S; Auteri A
    Ann Ital Med Int; 2005; 20(2):81-9. PubMed ID: 16052840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice.
    Ni W; Kitamoto S; Ishibashi M; Usui M; Inoue S; Hiasa K; Zhao Q; Nishida K; Takeshita A; Egashira K
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):534-9. PubMed ID: 14739122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammation, atherosclerosis, and stroke.
    Elkind MS
    Neurologist; 2006 May; 12(3):140-8. PubMed ID: 16688015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Markers of instability in high-risk carotid plaques are reduced by statins.
    Kunte H; Amberger N; Busch MA; Rückert RI; Meiners S; Harms L
    J Vasc Surg; 2008 Mar; 47(3):513-22. PubMed ID: 18295103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
    Díez J
    Clin Ther; 2006 Jun; 28(6):832-48. PubMed ID: 16860167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impaired fibrous repair: a possible contributor to atherosclerotic plaque vulnerability in patients with type II diabetes.
    Edsfeldt A; Gonçalves I; Grufman H; Nitulescu M; Dunér P; Bengtsson E; Mollet IG; Persson A; Nilsson M; Orho-Melander M; Melander O; Björkbacka H; Nilsson J
    Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):2143-50. PubMed ID: 25035341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional profile of activated dendritic cells in unstable atherosclerotic plaque.
    Erbel C; Sato K; Meyer FB; Kopecky SL; Frye RL; Goronzy JJ; Weyand CM
    Basic Res Cardiol; 2007 Mar; 102(2):123-32. PubMed ID: 17136419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin II as a pro-inflammatory mediator.
    Phillips MI; Kagiyama S
    Curr Opin Investig Drugs; 2002 Apr; 3(4):569-77. PubMed ID: 12090726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet activation, inflammatory mediators and hypercholesterolemia.
    Ferroni P; Basili S; Davi G
    Curr Vasc Pharmacol; 2003 Jun; 1(2):157-69. PubMed ID: 15320841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?
    Schönbeck U; Libby P
    Circulation; 2004 Jun; 109(21 Suppl 1):II18-26. PubMed ID: 15173059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability.
    Müller A; Krämer SD; Meletta R; Beck K; Selivanova SV; Rancic Z; Kaufmann PA; Vos B; Meding J; Stellfeld T; Heinrich TK; Bauser M; Hütter J; Dinkelborg LM; Schibli R; Ametamey SM
    Nucl Med Biol; 2014 Aug; 41(7):562-9. PubMed ID: 24853402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polyclonal origin of T lymphocytes in human atherosclerotic plaques.
    Stemme S; Rymo L; Hansson GK
    Lab Invest; 1991 Dec; 65(6):654-60. PubMed ID: 1836515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The role of infection and inflammation in the pathogenesis of atherosclerosis].
    Jaber J; Murín J; Kinová S; Gavorník P; Ghanem Wisam MA; Radman A; Gharaibeh A; Richter P
    Vnitr Lek; 2002 Jul; 48(7):657-66. PubMed ID: 12197410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Köenig W
    J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The promise of statins].
    Capurso A
    Ital Heart J Suppl; 2001 Mar; 2(3):224-9. PubMed ID: 11307780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statins and inflammatory markers.
    Case CC; Ballantyne CM
    Curr Atheroscler Rep; 2002 Jan; 4(1):42-7. PubMed ID: 11772421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Is arteriosclerosis an infectious disease?].
    Meniconi A; Noll G; Lüscher TF
    Praxis (Bern 1994); 1998 Jan; 87(3):64-74. PubMed ID: 9492588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins and direct vascular actions.
    Mueck AO; Seeger H
    Panminerva Med; 2003 Mar; 45(1):1-6. PubMed ID: 12682615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid-associated eye disease.
    Heufelder AE; Joba W
    Strabismus; 2000 Jun; 8(2):101-11. PubMed ID: 10980691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.